The Experts below are selected from a list of 252 Experts worldwide ranked by ideXlab platform
K. Hobby - One of the best experts on this subject based on the ideXlab platform.
-
double blind randomized controlled trial and six year open follow up of yttrium 90 radiosynovectomy versus Triamcinolone Hexacetonide in persistent rheumatoid knee synovitis
Inflammopharmacology, 1992Co-Authors: E. N. Grant, Nicholas Bellamy, T. Disney, A. Driedger, K Frydayfield, K. HobbyAbstract:Knee joints (n=30) from 22 adult rheumatoid arthritis (RA) patients who were previously randomized and subjected to a six-month double-blind controlled trial of yttrium-90 vs. Triamcinolone Hexacetonide with a six-year follow-up. In contrast to most previous studies, there was no co-administration of a steroid agent at the time the radiopharmaceutical was injected. One month after treatment the Triamcinolone group had less pain (p<0.05), fewer effusions (p<0.001) and a better range of movement (p<0.01) than the yttrium group. Six months after treatment, the response in the Triamcinolone group had partially regressed but was still superior to that of the yttrium group (p<0.05). At the six-year follow-up, half the yttrium-treated knees were found to have required treatment by intra-articular steroid, surgical synovectomy or total knee arthroplasty. The rates for therapeutic success were no different for yttrium-90 or Triamcinolone. These results bring into question the reported efficacy of yttrium-90 and suggest that the benefit observed in clinical practice may be dependent upon the co-administration of a corticosteroid agent, and that the long-term benefits of yttrium may be relatively small.
-
Double-blind randomized controlled trial and six-year open follow-up of yttrium-90 radiosynovectomy versus Triamcinolone Hexacetonide in persistent rheumatoid knee synovitis
Inflammopharmacology, 1992Co-Authors: E. N. Grant, Nicholas Bellamy, K. Fryday-field, T. Disney, A. Driedger, K. HobbyAbstract:Knee joints (n=30) from 22 adult rheumatoid arthritis (RA) patients who were previously randomized and subjected to a six-month double-blind controlled trial of yttrium-90 vs. Triamcinolone Hexacetonide with a six-year follow-up. In contrast to most previous studies, there was no co-administration of a steroid agent at the time the radiopharmaceutical was injected. One month after treatment the Triamcinolone group had less pain (p
Rita Nely Vilar Furtado - One of the best experts on this subject based on the ideXlab platform.
-
Time Effect of Intra-articular Injection With Triamcinolone Hexacetonide and Its Correlations: A Case-Control Prospective 12-Month Study.
American journal of physical medicine & rehabilitation, 2019Co-Authors: Roberta Hora Rocha, Jamil Natour, Rita M Dos Santos, Rita Nely Vilar FurtadoAbstract:ObjectiveThe aim of the study was to assess the time effect of intra-articular injection with Triamcinolone Hexacetonide in rheumatic patients.DesignA prospective case-control study with patients submitted to one intra-articular injection with Triamcinolone Hexacetonide. Patients were followed month
-
intra articular injection with Triamcinolone Hexacetonide in patients with rheumatoid arthritis prospective assessment of goniometry and joint inflammation parameters
Revista Brasileira De Reumatologia, 2017Co-Authors: Rita Nely Vilar Furtado, Marla Francisca Dos Santos, Monique Sayuri Konai, F.s. Machado, Karine Rodrigues Da Luz, Roberta Vilela Lopes, Jamil NatourAbstract:Objectives To evaluate local joint variables after intra-articular injection with Triamcinolone Hexacetonide in rheumatoid arthritis patients. Methods We blindly and prospectively (baseline, 1, 4, 12 and 24 weeks) evaluated metacarpophalangeal, wrist, elbow, shoulder, knee and ankle joints after Triamcinolone Hexacetonide intra-articular injection by the following outcome measures: visual analogue scale 0–10 cm (VAS) for rest pain (VASR); VAS for movement pain (VASM); VAS for joint swelling (VASSw); flexion (FlexG) and extension (ExtG). Results 289 patients (635 joints) were studied. VASSw (p < 0.001) and VASR (0.001 < p < 0.016) improved from T0 to T4, T12 and T24 for all joints. VASM improved from T0 to T4 (p < 0.021) for all joints; T0 to T12 (p < 0.023) for MCF and knee; T0 to T24 (p < 0.019) only for MCF and knee. FlexG improved from T0 to T4 (p < 0.001) for all joints; T0 to T12 (p < 0.001) and T0 to T24 (p < 0.02) only for MCF and knee. ExtG improved from T0 to T4 (p < 0.001) for all joints except for elbow; T0 to T12 (p = 0.003) for wrist, metacarpophalangeal and knee; and T0 to T24 (p = 0.014) for MCF and knee. Conclusion VASSw responded better at short and medium term after IAI with Triamcinolone Hexacetonide in our sample of RA patients.
-
Intra-articular injection with Triamcinolone Hexacetonide in patients with rheumatoid arthritis: prospective assessment of goniometry and joint inflammation parameters.
Revista brasileira de reumatologia, 2016Co-Authors: Rita Nely Vilar Furtado, Marla Francisca Dos Santos, Monique Sayuri Konai, F.s. Machado, Karine Rodrigues Da Luz, Roberta Vilela Lopes, Jamil NatourAbstract:Objectives To evaluate local joint variables after intra-articular injection with Triamcinolone Hexacetonide in rheumatoid arthritis patients. Methods We blindly and prospectively (baseline, 1, 4, 12 and 24 weeks) evaluated metacarpophalangeal, wrist, elbow, shoulder, knee and ankle joints after Triamcinolone Hexacetonide intra-articular injection by the following outcome measures: visual analogue scale 0–10 cm (VAS) for rest pain (VASR); VAS for movement pain (VASM); VAS for joint swelling (VASSw); flexion (FlexG) and extension (ExtG). Results 289 patients (635 joints) were studied. VASSw (p
-
Effectiveness of Triamcinolone Hexacetonide Intraarticular Injection in Interphalangeal Joints: A 12-week Randomized Controlled Trial in Patients with Hand Osteoarthritis.
The Journal of rheumatology, 2015Co-Authors: Natalia De Oliva Spolidoro Paschoal, F.s. Machado, Jamil Natour, H.a.v. Oliveira, Rita Nely Vilar FurtadoAbstract:Objective. To evaluate the effectiveness and tolerance of intraarticular injection (IAI) of Triamcinolone Hexacetonide (TH) for the treatment of osteoarthritis (OA) of hand interphalangeal (IP) joints. Methods. Sixty patients who underwent IAI at the most symptomatic IP joint were randomly assigned to receive TH/lidocaine (LD; n = 30) with TH 20 mg/ml and LD 2%, or just LD (n = 30). The injected joint was immobilized with a splint for 48 h in both groups. Patients were assessed at baseline and at 1, 4, 8, and 12 weeks by a blinded observer. The following variables were assessed: pain at rest [visual analog scale (VAS)r], pain at movement (VASm), swelling (physician VASs), goniometry, grip and pinch strength, hand function, treatment improvement, daily requirement of paracetamol, and local adverse effects. The proposed treatment (IAI with TH/LD) was successful if statistical improvement (p Results. Fifty-eight patients (96.67%) were women, and the mean age was 60.7 years (± 8.2). The TH/LD group showed greater improvement than the LD group for VASm (p = 0.014) and physician VASs (p = 0.022) from the first week until the end of the study. In other variables, there was no statistical difference between groups. No significant adverse effects were observed. Conclusion. The IAI with TH/LD has been shown to be more effective than the IAI with LD for pain on movement and joint swelling in patients with OA of the IP joints. Regarding pain at rest, there was no difference between groups. Trial registration number: ClinicalTrials.gov (NCT02102620).
-
Effectiveness of intra-articular injection in wrist joints according to Triamcinolone Hexacetonide dose in rheumatoid arthritis: a randomized controlled double-blind study.
American journal of physical medicine & rehabilitation, 2015Co-Authors: D.f. Pereira, Jamil Natour, Natália Pereira Machado, Rita Nely Vilar FurtadoAbstract:OBJECTIVE The aim of this study was to compare the effectiveness in the medium term between low and high doses of Triamcinolone Hexacetonide used in intra-articular injection in medium-sized joints of rheumatoid arthritis (RA) patients. METHODS A randomized double-blind study was carried out in rheumatoid arthritis patients with wrist painful refractory synovitis. Sixty wrists were included and randomized to receive low dose (20 mg) or high dose (40 mg). The outcomes assessed in T0, T1, T4, T8, and T12 weeks were visual analog scale for pain and for swelling, chronic disease activity index, goniometry, simplified Stanford Health Assessment Questionnaire, and side effects. RESULTS Baseline mean (standard deviation) values were pain visual analog scale of 6.1 (1.6) and 6.3 (1.7), P = 0.562; swelling visual analog scale of 5.9 and 6.4, P = 0.466; chronic disease activity index of 17.8 and 16.8, P = 0.366; and Health Assessment Questionnaire of 0.8 and 0.7, P = 0.238, in the high- and low-dose groups, respectively. Both groups improved pain and swelling assessed by the visual analog scale, P < 0.001, in the intragroup analysis. Chronic disease activity index, goniometry, and Health Assessment Questionnaire also improved equally over time in both groups in the intragroup analysis (P < 0.001, 0.001, and 0.002, respectively). No serious side effects were detected. CONCLUSIONS High and low Triamcinolone Hexacetonide doses had good effectiveness in wrist-blinded intra-articular injection of rheumatoid arthritis patients, without statistical difference between them.
E. N. Grant - One of the best experts on this subject based on the ideXlab platform.
-
double blind randomized controlled trial and six year open follow up of yttrium 90 radiosynovectomy versus Triamcinolone Hexacetonide in persistent rheumatoid knee synovitis
Inflammopharmacology, 1992Co-Authors: E. N. Grant, Nicholas Bellamy, T. Disney, A. Driedger, K Frydayfield, K. HobbyAbstract:Knee joints (n=30) from 22 adult rheumatoid arthritis (RA) patients who were previously randomized and subjected to a six-month double-blind controlled trial of yttrium-90 vs. Triamcinolone Hexacetonide with a six-year follow-up. In contrast to most previous studies, there was no co-administration of a steroid agent at the time the radiopharmaceutical was injected. One month after treatment the Triamcinolone group had less pain (p<0.05), fewer effusions (p<0.001) and a better range of movement (p<0.01) than the yttrium group. Six months after treatment, the response in the Triamcinolone group had partially regressed but was still superior to that of the yttrium group (p<0.05). At the six-year follow-up, half the yttrium-treated knees were found to have required treatment by intra-articular steroid, surgical synovectomy or total knee arthroplasty. The rates for therapeutic success were no different for yttrium-90 or Triamcinolone. These results bring into question the reported efficacy of yttrium-90 and suggest that the benefit observed in clinical practice may be dependent upon the co-administration of a corticosteroid agent, and that the long-term benefits of yttrium may be relatively small.
-
Double-blind randomized controlled trial and six-year open follow-up of yttrium-90 radiosynovectomy versus Triamcinolone Hexacetonide in persistent rheumatoid knee synovitis
Inflammopharmacology, 1992Co-Authors: E. N. Grant, Nicholas Bellamy, K. Fryday-field, T. Disney, A. Driedger, K. HobbyAbstract:Knee joints (n=30) from 22 adult rheumatoid arthritis (RA) patients who were previously randomized and subjected to a six-month double-blind controlled trial of yttrium-90 vs. Triamcinolone Hexacetonide with a six-year follow-up. In contrast to most previous studies, there was no co-administration of a steroid agent at the time the radiopharmaceutical was injected. One month after treatment the Triamcinolone group had less pain (p
J. C. Alves - One of the best experts on this subject based on the ideXlab platform.
-
Intraarticular Triamcinolone Hexacetonide, stanozolol, Hylan G-F 20 and platelet concentrate in a naturally occurring canine osteoarthritis model.
Scientific reports, 2021Co-Authors: J. C. Alves, Patrícia Jorge, Catarina Lavrador, A. Santos, L. Miguel CarreiraAbstract:Osteoarthritis (OA) is a disease transversal to all mammals, a source of chronic pain and disability, a huge burden to societies, with a significant toll in healthcare cost, while reducing productivity and quality of life. The dog is considered a useful model for the translational study of the disease, closely matching human OA, with the advantage of a faster disease progression while maintaining the same life stages. In a prospective, longitudinal, double-blinded, negative controlled study, one hundred (N = 100) hip joints were selected and randomly assigned to five groups: control group (CG, n = 20, receiving a saline injection), Triamcinolone Hexacetonide group (THG, n = 20), platelet concentrate group (PCG, n = 20), stanozolol group (SG, n = 20) and hylan G-F 20 group (HG). Evaluations were conducted on days 0 (T0, treatment day), 8, 15, 30, 60, 90, 120, 150 and 180 days post-treatment, consisting of weight distribution analysis and data from four Clinical Metrology Instruments (CMI). Kaplan-Meier estimators were generated and compared with the Breslow test. Cox proportional hazard regression analysis was used to investigate the influence of variables of interest on treatment survival. All results were analyzed with IBM SPSS Statistics version 20 and a significance level of p
-
intraarticular Triamcinolone Hexacetonide stanozolol hylan g f 20 and platelet concentrate in a naturally occurring canine osteoarthritis model
Scientific Reports, 2021Co-Authors: J. C. Alves, Patrícia Jorge, Catarina Lavrador, A. Santos, Miguel L CarreiraAbstract:Osteoarthritis (OA) is a disease transversal to all mammals, a source of chronic pain and disability, a huge burden to societies, with a significant toll in healthcare cost, while reducing productivity and quality of life. The dog is considered a useful model for the translational study of the disease, closely matching human OA, with the advantage of a faster disease progression while maintaining the same life stages. In a prospective, longitudinal, double-blinded, negative controlled study, one hundred (N = 100) hip joints were selected and randomly assigned to five groups: control group (CG, n = 20, receiving a saline injection), Triamcinolone Hexacetonide group (THG, n = 20), platelet concentrate group (PCG, n = 20), stanozolol group (SG, n = 20) and hylan G-F 20 group (HG). Evaluations were conducted on days 0 (T0, treatment day), 8, 15, 30, 60, 90, 120, 150 and 180 days post-treatment, consisting of weight distribution analysis and data from four Clinical Metrology Instruments (CMI). Kaplan-Meier estimators were generated and compared with the Breslow test. Cox proportional hazard regression analysis was used to investigate the influence of variables of interest on treatment survival. All results were analyzed with IBM SPSS Statistics version 20 and a significance level of p < 0.05 was set. Sample included joints of 100 pelvic limbs (of patients with a mean age of 6.5 ± 2.4 years and body weight of 26.7 ± 5.2 kg. Joints were graded as mild (n = 70), moderate (n = 20) and severe (n = 10) OA. No differences were found between groups at T0. Kaplan-Meier analysis showed that all treatments produced longer periods with better results in the various evaluations compared to CG. Patients in HG and PCG took longer to return to baseline values and scores. A higher impact on pain interference was observed in THG, with a 95% improvement over CG. PCG and HG experienced 57-81% improvements in functional evaluation and impairments due to OA, and may be a better options for these cases. This study documented the efficacy of several approaches to relieve OA clinical signs. These approaches varied in intensity and duration. HG and PCG where the groups were more significant improvements were observed throughout the follow-up periods, with lower variation in results.
-
Correction: The intra-articular administration of Triamcinolone Hexacetonide in the treatment of osteoarthritis. Its effects in a naturally occurring canine osteoarthritis model.
PloS one, 2021Co-Authors: J. C. Alves, Ana Paula Pires Dos Santos, Patrícia Jorge, Catarina Lavrador, L. Miguel CarreiraAbstract:Objective To evaluate the effect of an intra-articular (IA) administration of Triamcinolone Hexacetonide, compared with saline. Patients and methods Forty (N = 40) hip joints were randomly assigned to a treatment group (THG, n = 20, receiving IA Triamcinolone Hexacetonide) and a control group (CG, n = 20, receiving IA saline). On treatment day (T0), and at 8, 15, 30, 90 and 180 days post-treatment, weight distribution, joint range of motion, thigh girth, digital thermography, radiographic signs, synovial fluid interleukin-1 and C-reactive protein levels were evaluated. Data from four Clinical Metrology Instruments was also gathered. Results were compared Repeated Measures ANOVA, with a Huynh-Feldt correction, Paired Samples T-Test or Wilcoxon Signed Ranks Test. A Kaplan-Meier test was performed to compare both groups, with p
-
correction the intra articular administration of Triamcinolone Hexacetonide in the treatment of osteoarthritis its effects in a naturally occurring canine osteoarthritis model
PLOS ONE, 2021Co-Authors: J. C. Alves, Ana Paula Pires Dos Santos, Patrícia Jorge, Catarina Lavrador, Miguel L CarreiraAbstract:Objective To evaluate the effect of an intra-articular (IA) administration of Triamcinolone Hexacetonide, compared with saline. Patients and methods Forty (N = 40) hip joints were randomly assigned to a treatment group (THG, n = 20, receiving IA Triamcinolone Hexacetonide) and a control group (CG, n = 20, receiving IA saline). On treatment day (T0), and at 8, 15, 30, 90 and 180 days post-treatment, weight distribution, joint range of motion, thigh girth, digital thermography, radiographic signs, synovial fluid interleukin-1 and C-reactive protein levels were evaluated. Data from four Clinical Metrology Instruments was also gathered. Results were compared Repeated Measures ANOVA, with a Huynh-Feldt correction, Paired Samples T-Test or Wilcoxon Signed Ranks Test. A Kaplan-Meier test was performed to compare both groups, with p<0.05. Results Joints were graded as mild (65%), moderate (20%) and severe (15%). Patients of both sexes, with a mean age of 6.5±2.4 years and bodyweight of 26.7±5.2kg, were included. No differences were found between groups at T0. Comparing THG to CG, weight distribution showed significant improvements in THG from 8 (p = 0.05) up to 90 days (p = 0.01). THG showed lower values during thermographic evaluation in the Lt view (p<0.01). Pain and function scores also improved from 30 to 180 days. Increasing body weight, age, and presence of caudolateral curvilinear osteophyte corresponded to worse response to treatment. Results of the Kaplan Meier test showed significant differences between groups, with THG performing better considering several evaluations and scores. Conclusion THG recorded significant improvements in weight-bearing and in with the considered CMIs, particularly pain scores. Lower thermographic values were registered in THG up to the last evaluation day. Age, sex, and radiographic findings did significantly influenced response to treatment.
-
Intra-articular Injections With Either Triamcinolone Hexacetonide, Stanozolol, Hylan G-F 20, or a Platelet Concentrate Improve Clinical Signs in Police Working Dogs With Bilateral Hip Osteoarthritis.
Frontiers in veterinary science, 2021Co-Authors: J. C. Alves, Ana Paula Pires Dos Santos, Patrícia Jorge, Catarina Lavrador, L. Miguel CarreiraAbstract:Objectives: To compare the effect of intra-articular treatment with Triamcinolone Hexacetonide (TH), stanozolol, hyaluronan, and a platelet concentrate in police working dogs with bilateral hip osteoarthritis (OA). Study Design: Prospective, longitudinal, double-blinded, negative controlled study. Sample Population: Fifty police working dogs with naturally occurring hip OA. Methods: Animals were randomly assigned to a control group (CG, n = 10), TH group (THG, n = 10), platelet concentrate group (PCG, n = 10), stanozolol group (SG, n = 10), and Hylan G-F 20 group (HG). On days 0 (T0), 8, 15, 30, 90, and 180 days post-treatment, weight-bearing distribution was evaluated. In those days, and on days 60, 120, and 150, four clinical metrology instruments were completed. Kaplan-Meier estimators were conducted and compared with the log-rank test. Cox proportional hazard regression analysis was performed to determine treatment survival. Significance was set at p < 0.05. Results: Patients had a mean age of 6.5 ± 2.4 years and body weight of 26.7 ± 5.2 kg. At T0, hips were classified as mild (n = 35), moderate (n = 10), and severe (n = 5), according to the Orthopedic Foundation for Animals grading scheme. No differences were found between groups at that moment considering age, body weight, OFA hip score, and all assessments performed. All treatments improved clinical signs in various OA dimensions in some groups, with a broad effect interval. PCG showed a lower range of variation while maintaining a positive result for more extended periods (p < 0.01 for symmetry index and 0.01 < p < 0.04 in the majority of scores). Breed, age, sex, and OFA grade did not significantly influence response to treatment. Conclusions and Clinical Relevance: This is the first prospective, negative controlled, double-blinded study to compare the effect of a single administration of these IA treatments in dogs with hip OA. HG and PCG recorded more significant improvements throughout the 180-day follow-up. In particular, PCG also registered a lower variation in results, seemingly the best therapeutic option. Nevertheless, improvements were still observed in THG and SG, and these treatment options can be considered, mainly when the first two treatments are not available.
L. Miguel Carreira - One of the best experts on this subject based on the ideXlab platform.
-
Intraarticular Triamcinolone Hexacetonide, stanozolol, Hylan G-F 20 and platelet concentrate in a naturally occurring canine osteoarthritis model.
Scientific reports, 2021Co-Authors: J. C. Alves, Patrícia Jorge, Catarina Lavrador, A. Santos, L. Miguel CarreiraAbstract:Osteoarthritis (OA) is a disease transversal to all mammals, a source of chronic pain and disability, a huge burden to societies, with a significant toll in healthcare cost, while reducing productivity and quality of life. The dog is considered a useful model for the translational study of the disease, closely matching human OA, with the advantage of a faster disease progression while maintaining the same life stages. In a prospective, longitudinal, double-blinded, negative controlled study, one hundred (N = 100) hip joints were selected and randomly assigned to five groups: control group (CG, n = 20, receiving a saline injection), Triamcinolone Hexacetonide group (THG, n = 20), platelet concentrate group (PCG, n = 20), stanozolol group (SG, n = 20) and hylan G-F 20 group (HG). Evaluations were conducted on days 0 (T0, treatment day), 8, 15, 30, 60, 90, 120, 150 and 180 days post-treatment, consisting of weight distribution analysis and data from four Clinical Metrology Instruments (CMI). Kaplan-Meier estimators were generated and compared with the Breslow test. Cox proportional hazard regression analysis was used to investigate the influence of variables of interest on treatment survival. All results were analyzed with IBM SPSS Statistics version 20 and a significance level of p
-
Correction: The intra-articular administration of Triamcinolone Hexacetonide in the treatment of osteoarthritis. Its effects in a naturally occurring canine osteoarthritis model.
PloS one, 2021Co-Authors: J. C. Alves, Ana Paula Pires Dos Santos, Patrícia Jorge, Catarina Lavrador, L. Miguel CarreiraAbstract:Objective To evaluate the effect of an intra-articular (IA) administration of Triamcinolone Hexacetonide, compared with saline. Patients and methods Forty (N = 40) hip joints were randomly assigned to a treatment group (THG, n = 20, receiving IA Triamcinolone Hexacetonide) and a control group (CG, n = 20, receiving IA saline). On treatment day (T0), and at 8, 15, 30, 90 and 180 days post-treatment, weight distribution, joint range of motion, thigh girth, digital thermography, radiographic signs, synovial fluid interleukin-1 and C-reactive protein levels were evaluated. Data from four Clinical Metrology Instruments was also gathered. Results were compared Repeated Measures ANOVA, with a Huynh-Feldt correction, Paired Samples T-Test or Wilcoxon Signed Ranks Test. A Kaplan-Meier test was performed to compare both groups, with p
-
Intra-articular Injections With Either Triamcinolone Hexacetonide, Stanozolol, Hylan G-F 20, or a Platelet Concentrate Improve Clinical Signs in Police Working Dogs With Bilateral Hip Osteoarthritis.
Frontiers in veterinary science, 2021Co-Authors: J. C. Alves, Ana Paula Pires Dos Santos, Patrícia Jorge, Catarina Lavrador, L. Miguel CarreiraAbstract:Objectives: To compare the effect of intra-articular treatment with Triamcinolone Hexacetonide (TH), stanozolol, hyaluronan, and a platelet concentrate in police working dogs with bilateral hip osteoarthritis (OA). Study Design: Prospective, longitudinal, double-blinded, negative controlled study. Sample Population: Fifty police working dogs with naturally occurring hip OA. Methods: Animals were randomly assigned to a control group (CG, n = 10), TH group (THG, n = 10), platelet concentrate group (PCG, n = 10), stanozolol group (SG, n = 10), and Hylan G-F 20 group (HG). On days 0 (T0), 8, 15, 30, 90, and 180 days post-treatment, weight-bearing distribution was evaluated. In those days, and on days 60, 120, and 150, four clinical metrology instruments were completed. Kaplan-Meier estimators were conducted and compared with the log-rank test. Cox proportional hazard regression analysis was performed to determine treatment survival. Significance was set at p < 0.05. Results: Patients had a mean age of 6.5 ± 2.4 years and body weight of 26.7 ± 5.2 kg. At T0, hips were classified as mild (n = 35), moderate (n = 10), and severe (n = 5), according to the Orthopedic Foundation for Animals grading scheme. No differences were found between groups at that moment considering age, body weight, OFA hip score, and all assessments performed. All treatments improved clinical signs in various OA dimensions in some groups, with a broad effect interval. PCG showed a lower range of variation while maintaining a positive result for more extended periods (p < 0.01 for symmetry index and 0.01 < p < 0.04 in the majority of scores). Breed, age, sex, and OFA grade did not significantly influence response to treatment. Conclusions and Clinical Relevance: This is the first prospective, negative controlled, double-blinded study to compare the effect of a single administration of these IA treatments in dogs with hip OA. HG and PCG recorded more significant improvements throughout the 180-day follow-up. In particular, PCG also registered a lower variation in results, seemingly the best therapeutic option. Nevertheless, improvements were still observed in THG and SG, and these treatment options can be considered, mainly when the first two treatments are not available.
